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Abstract
Background: The benefit-risk ratio has been proposed to measure the tradeoff between benefits
and risks of two therapies for a single binary measure of efficacy and a single adverse event. The
ratio is calculated from the difference in risk and difference in benefit between therapies. Small
sample sizes or expected differences in benefit or risk can lead to no solution or problematic
solutions for confidence intervals.
Methods: Alternatively, using the joint distribution of benefit and risk, confidence regions for the
differences in risk and benefit can be constructed in the benefit-risk plane. The information in the
joint distribution can be summarized by choosing regions of interest in this plane. Using Bayesian
methodology provides a very flexible framework for summarizing information in the joint
distribution.
Results:  Data from a National Institute of Child Health & Human Development trial of
hydrocortisone illustrate the construction of confidence regions and regions of interest in the
benefit-risk plane, where benefit is survival without supplemental oxygen at 36 weeks
postmenstrual age, and risk is gastrointestinal perforation. For the subgroup of infants exposed to
chorioamnionitis the confidence interval based on the benefit-risk ratio is wide (Benefit-risk ratio:
1.52; 90% confidence interval: 0.23 to 5.25). Choosing regions of appreciable risk and acceptable
risk in the benefit-risk plane confirms the uncertainty seen in the wide confidence interval for the
benefit-risk ratio – there is a greater than 50% chance of falling into the region of acceptable risk –
while visually allowing the uncertainty in risk and benefit to be shown separately. Applying Bayesian
methodology, an incremental net health benefit analysis shows there is a 72% chance of having a
positive incremental net benefit if hydrocortisone is used in place of placebo if one is willing to incur
at most one gastrointestinal perforation for each additional infant that survives without
supplemental oxygen.
Conclusion: If the benefit-risk ratio is presented, the joint distribution of benefit and risk also
should be shown. These regions avoid the ambiguity associated with collapsing benefit and risk to
a single dimension. Bayesian methods allow even greater flexibility in simultaneously quantifying
benefit and risk.
Published: 12 October 2006
BMC Medical Research Methodology 2006, 6:48 doi:10.1186/1471-2288-6-48
Received: 15 August 2006
Accepted: 12 October 2006
This article is available from: http://www.biomedcentral.com/1471-2288/6/48
© 2006 Shaffer and Watterberg; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Medical Research Methodology 2006, 6:48 http://www.biomedcentral.com/1471-2288/6/48
Page 2 of 8
(page number not for citation purposes)
Background
When comparing the effects of a new therapy with an
existing therapy, it is not uncommon for the new therapy
to show increased risks along with increased benefits. We
consider the case of a single binary measure of efficacy
and a single binary measure of risk or adverse event
(absent/present, ever/never) and address the questions:
1. How do you appropriately measure the tradeoff
between the benefit and risk of two therapies?
2. When should you conclude the increased benefit of a
new therapy outweighs the potential increased risk?
Rather than focusing on hypothesis testing and control-
ling the type I error rate, our interest is in jointly quantify-
ing benefit and risk.
The benefit-risk ratio
One method that has been suggested for measuring the
tradeoff between a binary measure of benefit and a binary
measure of risk is the benefit-risk ratio [1]. The benefit-
risk ratio is the ratio of the difference in benefit to differ-
ence in risk, or equivalently, the ratio of Number Needed
to Harm (NNH) to Number Needed to Treat (NNT):
where  pE and  pc are the probabilities of benefit in the
experimental treatment and control arms, respectively,
and qE and qc are the probabilities of risk in the experimen-
tal treatment and control arms, respectively.
The benefit-risk ratio can be interpreted as the increase in
the number of expected patients who will benefit for each
additional adverse event that is incurred from using the
experimental treatment rather than the control. The ratio
also can be viewed in the benefit-risk plane as the slope of
the line that passes through the origin and point defined
by the observed difference in risk and difference in benefit
as shown in Figure 1. The benefit-risk ratio is similar to the
incremental cost-effectiveness ratio (ICER), which meas-
ures the tradeoff between the cost and effectiveness of two
therapies. The ICER is defined as the ratio of the mean
treatment difference in cost to the mean treatment differ-
ence in effectiveness for two therapies:
where γE and γC are average costs of the experimental and
control conditions, respectively, and εEand εC are average
effectiveness measures of the experimental and control
conditions, respectively. One can similarly view the ICER
in the cost-effectiveness plane. Distributional assump-
tions may differ for the benefit-risk ratio and cost-effec-
tiveness ratio with cost generally considered a continuous
measure. And while effectiveness appears in the denomi-
nator of the ICER, benefit is in the numerator of the ben-
efit-risk ratio. Furthermore, although the current
discussion focuses on a single binary measure of risk, con-
solidating multiple risks into a single measure may be
more problematic than combining costs.
There is some ambiguity in reducing the difference in ben-
efit and difference in risk to a single measure. As differing
magnitudes of benefit and risk can result in the same
ratio, control therapy could show more benefit and more
risk and yield the same ratio as a new therapy which
shows more benefit and more risk. Note in Figure 1 that
any observed difference in benefit and observed difference
in risk that falls on the line shown through the origin will
produce the same benefit-risk ratio. For example, suppose
the difference in benefit favors the new therapy over con-
trol and is 0.30, but the new therapy also increases the
adverse event rate by 0.20; the resulting benefit-risk ratio
is 1.5. However, if the difference in benefit favors control
over the new therapy and is -0.30, but the new therapy
reduces the adverse event rate by 0.20, then the resulting
benefit risk ratio also is 1.5. When deciding whether the
new therapy is acceptable, it is unlikely that these two sce-
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The benefit-risk ratio in the benefit-risk plane Figure 1
The benefit-risk ratio in the benefit-risk plane. The 
benefit-risk ratio is the slope of the line which passes through 
the origin and the point defined by the observed difference in 
risk and observed difference in benefit.
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narios would be considered equivalent. In the first sce-
nario we are weighing increased benefit against increased
risk, while in the latter we are weighing decreased benefit
against decreased risk. Heitjan et al. highlighted similar
complications for estimation of the ICER [2].
Confidence intervals can be constructed for the benefit-
risk ratio using methods similar to those used to compute
confidence intervals for cost-effectiveness ratios [3-5].
Assuming bivariate normality, Willan et al. showed that
Fieller's theorem can be used to compute confidence
intervals where the variance of the bivariate normal distri-
bution is given by
where "hats" indicate the observed values of population
parameters and bE and bC are the probabilities of simulta-
neous benefit and risk in the same subject for the experi-
mental treatment and control arms, respectively [1]. The
variance is estimated ( ) by replacing the population
parameters with the observed values. Calculation of the
confidence limits by Fieller's theorem involves matrix
manipulation which can be done in several packages
including PROC IML in SAS (SAS Institute, Inc., Cary,
NC), Mathematica (Wolfram Research, Inc., Champaign,
IL), S-PLUS (Insightful Corporation, Seattle, WA), or the
free software R [6]. Alternatively, the bootstrap can be
used to construct confidence intervals using the percentile
method [7].
Difficulties can arise in using either Fieller's theorem or
the bootstrap methods to construct confidence intervals
[1,8,4,2,9]. Intractable or problematic solutions can result
using Fieller's theorem because of small sample sizes and/
or small expected differences in benefit and/or risk. As
shown in Figure 2, the confidence limits of the benefit-risk
ratio also can be represented as slopes of lines in the ben-
efit-risk plane, and there is a discontinuity in the distribu-
tion of the benefit-risk ratio when the difference in risk is
0. For the bootstrap method, it may be unclear how to
order estimates from the bootstrap samples when they fall
in multiple quadrants. Heitjan et al. proposed reordering
the bootstrap samples for the ICER (modified percentile
bootstrap), taking into account the quadrant in which the
ratio falls [4]. A more complete solution by Heitjan et al.
uses Bayesian methodology and treats the ICER as a two-
dimensional parameter composed of the ICER value and
the quadrant in which the effectiveness difference and
cost difference fall [2]. This methodology has been
extended to handle censored effectiveness data [9].
Other simultaneous measures of benefit and risk
Other measures have been suggested to summarize differ-
ences in benefit and risk. An early example is the work by
Tallarida et al. on a severity scale developed through phy-
sician interviews which synthesizes information on dis-
ease severity and adverse drug reactions so that these
considerations can be quantitatively incorporated into a
benefit-risk analysis [10]. Chuang-Stein et al. presented
three ratio measures that require assigning weights to cat-
egories of the form: (1) benefit without adverse event, (2)
benefit with adverse event, (3) no benefit and no adverse
event, (4) no benefit with adverse event, and (5) unac-
ceptable adverse event leading to withdrawal [11]. While
these ratios are more general than the benefit-risk ratio,
specifying weights that reflect the relative importance of
the categories may be difficult. Later work by Chuang-
Stein discounts benefit by risk using consolidated safety
data [12,13]. As noted by Holden, these approaches do
not clearly delineate benefit and risk which makes their
interpretation more complicated than the traditional ben-
efit-risk ratio [14].
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Confidence limits in the benefit-risk plane Figure 2
Confidence limits in the benefit-risk plane. The confi-
dence limits of the benefit-risk ratio can be represented as 
slopes of lines (dotted) which pass through the origin. A dis-
continuity exists when the difference in risk is 0.
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Methods
Confidence regions
Rather than collapsing the difference in benefit and differ-
ence in risk into a single dimension, the joint density of
benefit and risk can be represented in the benefit-risk
plane. Similar methods have been proposed for cost-effec-
tiveness analyses [15,16]. Confidence regions can be con-
structed either under the bivariate normal assumption or
using the bootstrap and nonparametric density estima-
tion. Assuming bivariate normality, the confidence region
is an ellipse. To construct a nonparametric confidence
region, we draw repeated (bootstrap) samples with
replacement and compute a benefit difference and risk
difference for each of the samples. Next we obtain a two-
dimensional kernel density estimate using the set of boot-
strap estimates and find a contour of the kernel density
estimate that includes (1 - α) × 100% of the bootstrap esti-
mates [17]. Two-dimensional kernel density estimation
methods are available for S-PLUS or R.
In addition to plotting the confidence region in the bene-
fit-risk plan, we also can partition the benefit-risk plane
into chosen regions of interest, e.g.,
1. Appreciable risk
2. No appreciable benefit
3. No conclusion ("gray region")
4. Experimental therapy superior
and look at the proportion of bootstrap estimates that fall
into each region. These regions may be easier to specify for
the clinician than the weights needed for the weighted
benefit-risk ratios proposed by Chuang-Stein et al. [11].
Bayesian methods
As an alternative to the confidence region approach, using
asymptotic theory, Bayesian inference can be based on the
posterior distribution of the difference in benefit and dif-
ference in risk, assuming that the prior distribution is
locally uniform (or continuous and nonzero) near the
true difference in risk and difference in benefit [18]. Using
the posterior distribution,
the posterior probability of falling into the chosen regions
can be computed [19]. The integration required can be
carried out using the numerical integration function N
Integrate in Mathematica or similar software. The proba-
bility interpretation of the Bayesian analysis is more
straightforward than the confidence interpretation associ-
ated with the bootstrapping approach.
Decision analysis also can be conducted under the Baye-
sian framework using linear combinations of the form
f(A, B) = A(pE - pC) - B(qE - qC)
Point estimates and probability intervals for these linear
combinations can be computed by taking a large number
of draws from the posterior distribution and computing
f(A, B) for each draw. The median of the draws can be
used as a point estimate of f(A, B), and the 100α/2 and
100(1 - α/2) centiles of these draws form a 100(1 - α)%
interval estimate.
These linear combinations also can be used to conduct
benefit-risk analyses analogous to the incremental net
health benefit (INHB)approach used in cost-effectiveness
analyses [20,21]. In the cost-effectiveness setting, the
INHB of an experimental treatment compared to a control
is defined as
INHB(λ) = (εE - εC) - (γE - γC)/λ
where λ can be thought of as the maximum society is will-
ing to pay for an incremental gain in health [20]. One
obvious advantage of this approach is that INHB is meas-
ured in units of effectiveness so the quadrant ambiguity of
the cost-effectiveness approach is no longer an issue.
Analogously, in the benefit-risk setting, we'll define an
incremental health benefit of the experimental therapy
compared to the control as
INHBBR(δ) = (pE - pC) - (qE - qC)/δ
where δ can be thought of as the maximum number of
adverse events one is willing to incur for each subject that
benefits. Alternatively, and perhaps more meaningfully,
one can interpret 1/δ as the minimum number of subjects
who should benefit for each additional adverse event.
Integration over the posterior distribution of the risk dif-
ference and benefit difference can be used to compute
Pr[INHBBR(δ) > 0] for a particular δ value or one can look
at a plot of Pr[INHBBR(δ) > 0] over a range of δ values.
Although we have used large sample theory to assume the
posterior distribution of the difference in risk and differ-
ence in benefit is bivariate normal, this assumption is not
necessary for these Bayesian methods. As long as it is pos-
sible to simulate draws from the posterior distribution,
these point estimates and probability intervals can be cal-
culated under other distributional assumptions. Simula-
tion approximations to the integration required to
compute the posterior probabilities, Pr[INHBBR(δ) > 0],
are obtained by computing the percentage of simulation
draws for which INHBBR(δ) exceeds 0. Similar simulation
p q qp p q qp p N q qp p EC EC EC EC EC EC ([ , ] |[ˆˆ , ˆˆ ]) ( [ˆˆ , ˆˆ ], −− ′ −− ′ ≈−−′ ˆ ˆ) VBMC Medical Research Methodology 2006, 6:48 http://www.biomedcentral.com/1471-2288/6/48
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approximations to integration can be used to compute
posterior probabilities of falling into chosen regions of
interest in the benefit-risk plane.
Results and discussion
The PROPHET study is a multicenter, randomized clinical
trial comparing placebo (n = 180) to low-dose hydrocor-
tisone therapy (n = 180) in the first two weeks of life in
extremely low birth weight babies (500–999 grams) to
prevent chronic lung disease sponsored by National Insti-
tute of Child Health & Human Development [22]. Enroll-
ment was stopped at 360 babies because of an increase in
spontaneous gastrointestinal (GI) perforation in the
hydrocortisone-treated group. The primary benefit out-
come for the study was survival without supplemental
oxygen at 36 weeks postmenstrual age. While low-dose
hydrocortisone did not significantly improve survival
without supplemental oxygen in the overall study popula-
tion, within the subgroup of babies exposed to chorioam-
nionitis (an a priori subgroup of interest), the
hydrocortisone-treated group had significantly higher sur-
vival without supplemental oxygen. A benefit-risk analy-
sis allows further examination of the relationship between
survival without supplemental oxygen and GI perforation
in the chorioamnionitis subgroup. Table 1 shows the pro-
portion of babies exposed to chorioamnionitis in each
treatment group that showed benefit or experienced a GI
perforation.
Using Fieller's theorem, the benefit-risk ratio for the chor-
ioamnionitis subgroup is 1.52 (90% confidence interval:
0.23 to 5.25). Thus, about 3 additional babies will survive
without supplemental oxygen for every 2 GI perforations
incurred from using hydrocortisone instead of placebo.
We note in this case that the confidence interval is wide
and is not inconsistent with as many as 5 babies benefit-
ing for each additional adverse event incurred when
hydrocortisone is used in place of placebo. The 90% con-
fidence ellipse assuming bivariate normality and 90%
nonparametric confidence region based on 5000 boot-
strap samples are shown in Figure 3. The bootstrap esti-
mates for the 5000 samples also are shown. Despite the
small expected cell counts for GI perforations in the pla-
cebo and hydrocortisone groups, for this example the
nonparametric and bivariate normal regions are very sim-
ilar.
As a hypothetical example of choosing regions of interest
for the PROPHET study, we separate the benefit-risk plane
into the following regions:
1. Appreciable Risk: Risk difference > 0.10
2. Acceptable Risk: Risk difference ≤ 0.10
a. Hydrocortisone Superior: Benefit difference > 0.20
b. No Conclusion: 0.10 ≤ Benefit difference ≤ 0.20
c. No Appreciable Benefit: Benefit difference < 0.10
Estimates of the probabilities of falling into the selected
regions are given in Table 2. The bootstrap proportions
and posterior probabilities are similar and show that there
is a greater than 50% chance of falling into the region of
acceptable risk. However, within the acceptable risk
region there is still a substantial chance that no conclusion
can be reached.
Alternatively, Figure 4 shows a plot of the probability the
incremental net health benefit (INHBBR) of hydrocorti-
sone compared to placebo exceeds zero over a range of 1/
δ, which can be interpreted here as the minimum number
of babies who should survive without supplemental oxy-
gen for each additional GI perforation incurred. If the
threshold is one additional survivor without supplemen-
tal oxygen for each additional GI perforation, the proba-
bility INHBBR(1)exceeds zero is approximately 0.72. This
probability quickly drops off and falls below 50% when
the threshold is approximately 1.5 additional survivors
without supplemental oxygen for each additional GI per-
foration.
These findings are not conclusive and demonstrate the
need for additional study to determine how hydrocorti-
sone therapy might be used to provide benefit in these
extremely low birth weight infants without increasing risk
of GI perforation. One area of potential investigation is
related to indomethacin therapy's role in the develop-
ment of GI perforation. There is evidence in the PROPHET
study of an interaction between hydrocortisone and early
indomethacin therapy, although indomethacin was not
randomized in this trial. In the absence of early indometh-
acin, low-dose hydrocortisone therapy administered as
Table 1: Survival without supplemental oxygen and GI perforation rates in the PROPHET study by treatment
Placebo (n = 76) Hydrocortisone (n = 73)
Survival without O2 18/76 (24%) 28/73 (38%)
GI Perforation 1/76 (1%) 8/73 (11%)
Survival without O2 and GI Perforation 0/76 3/73 (4%)BMC Medical Research Methodology 2006, 6:48 http://www.biomedcentral.com/1471-2288/6/48
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described for this study has not previously been associated
with increased incidence of GI perforation [23]. For this
analysis S-PLUS was used to construct the confidence
ellipse and nonparametric region. The two-dimensional
kernel density estimation function kde  and the ellipse-
drawing function ellipse for S-PLUS or R are available from
Table 2: Estimated probabilities of falling into selected regions of interest
Region Proportion of Bootstrap Estimates Posterior Probability
Appreciable risk 0.44 0.46
Hydrocortisone superior 0.14 0.13
No conclusion 0.27 0.27
No appreciable benefit 0.15 0.14
Total 1 1
Confidence regions and bootstrap estimates for the PROPHET study Figure 3
Confidence regions and bootstrap estimates for the PROPHET study. 90% confidence regions and bootstrap esti-
mates for the PROPHET study.
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StatLib [24]. Mathematica was used to compute the bene-
fit-risk ratio and associated confidence interval and all
posterior probabilities, but these computations also can
be done using S-PLUS or R.
Conclusion
It is less ambiguous to jointly look at the difference in risk
and difference in benefit in the benefit-risk plane than to
collapse information by computing a benefit-risk ratio. If
the benefit-risk ratio is reported, the joint distribution of
benefit and risk also should be presented. When looking
at the joint distribution, uncertainty in benefits and risks
can be represented by confidence ellipses based on the
assumption of bivariate normality or plots of estimates
from bootstrap samples with or without a nonparametric
confidence region. To quantify the probability of falling
into regions of interest, the proportion of bootstrap esti-
mates or posterior probabilities can be computed for par-
ticular regions. Bayesian methods provide a flexible
framework in which to summarize the joint distribution
of benefit and risk. Using the Bayesian framework allows
one to easily conduct benefit-risk analyses similar to the
incremental net health benefit analyses used for cost-
effectiveness research. As this approach is based on linear
combinations of benefit and risk, many of the inferential
problems associated with ratios are avoided.
We have chosen to focus on the comparison of two thera-
pies for a binary measure of benefit and a binary measure
of risk, as the motivating PROPHET study had a binary
primary benefit outcome and an increased rate of a single
adverse event, spontaneous GI perforation, which
resulted in an early stop of the trial. However, the Baye-
sian methods easily generalize to allow for other distribu-
tions of benefit and risk, provided one can simulate
samples from the posterior distribution of interest. The
Bayesian methods also allow prior information to be
incorporated into the inference if such information is
available. When it is of interest to compare more than two
therapies, the benefit-risk approaches shown can be con-
ducted in a pairwise fashion.
PR[INHBBR(δ) > 0] over a range of 1/δ values for the PROPHET study Figure 4
PR[INHBBR(δ) > 0] over a range of 1/δ values for the PROPHET study. Posterior probabilities that the incremental net 
health benefit (INHBBR) of hydrocortisone compared to placebo exceeds zero as a function of the minimum number of babies 
who should survive without supplemental oxygen for each additional GI perforation.
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